Pierre-Yves Berclaz, Chief Science and Medical Officer at Ferring Pharmaceuticals, stated: "The ADAPT-1 trial results confirm the efficacy and safety of follitropin delta across the full range of ...

The ADAPT-1 trial was a multicentre, randomised, assessor-blind study involving 300 women aged 18-40 years undergoing IVF or ICSI. 3 The trial compared the efficacy and safety of follitropin delta ...

These data build on previous studies which have established an estimated point of clinical correspondence for 10 µg follitropin delta to 150 IU follitropin alfa in this class of medications. 1,2 ...

Ferring Pharmaceuticals officially opened doors to its state-of-the-art gene therapy manufacturing facility in Parsippany ...

Our expert pharmacist warns against mixing these medications with your morning cup of coffee.

Ferring Pharmaceuticals presented the initial results from an ongoing Phase 3 trial (NCT05704244) in Japan assessing the efficacy and safety of ADSTILADRIN® (nadofaragene firadenovec-vncg) in ...

Ferring achieved total revenues of €2.3 billion in 2024, an increase of 7% over the previous year at actual exchange rates (AER) and 8% at constant exchange rates (CER). This above market growth ...

Ferring achieved record sales driven by Reproductive Medicine combined with the emergence of Adstiladrin For more information, please contact Carine Julen Senior Manager, Corporate Communications ...

Ferring activates first sites in a three-arm study of ADSTILADRIN as a monotherapy or in combination with chemotherapy or an immune checkpoint inhibitor in high-risk Bacillus Calmette-Guérin (BCG ...